🇺🇸 Transarterial Chemoembolization in United States
6 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 6
Most-reported reactions
- Abdominal Pain — 2 reports (33.33%)
- Depressed Mood — 1 report (16.67%)
- Liver Abscess — 1 report (16.67%)
- Pyrexia — 1 report (16.67%)
- Sepsis — 1 report (16.67%)
Other Oncology approved in United States
Frequently asked questions
Is Transarterial Chemoembolization approved in United States?
Transarterial Chemoembolization does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Transarterial Chemoembolization in United States?
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's is the originator. The local marketing authorisation holder may differ — check the official source linked above.